Cargando…

E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6

BACKGROUND: Some studties reported that the polymorphism of TM6SF2 gene E167K affects the occurrence and the progression of hepatocytes carcinoma (hepatocellular, HCC). In oeder to investigate the effects of the polymorphism of TM6SF2 gene E167K in the pathogenesis of HCC, we explored its influence...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Shuixian, Lu, Linlin, Miao, Yingxia, Jin, Wenwen, Li, Changfei, Xin, Yongning, Xuan, Shiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390375/
https://www.ncbi.nlm.nih.gov/pubmed/28407767
http://dx.doi.org/10.1186/s12944-017-0468-8
_version_ 1782521446337085440
author Du, Shuixian
Lu, Linlin
Miao, Yingxia
Jin, Wenwen
Li, Changfei
Xin, Yongning
Xuan, Shiying
author_facet Du, Shuixian
Lu, Linlin
Miao, Yingxia
Jin, Wenwen
Li, Changfei
Xin, Yongning
Xuan, Shiying
author_sort Du, Shuixian
collection PubMed
description BACKGROUND: Some studties reported that the polymorphism of TM6SF2 gene E167K affects the occurrence and the progression of hepatocytes carcinoma (hepatocellular, HCC). In oeder to investigate the effects of the polymorphism of TM6SF2 gene E167K in the pathogenesis of HCC, we explored its influence on the cell cycle in hepatocellular carcinoma cell HEPA1-6. METHODS: HEPA 1–6 cells which could respectively overexpress TM6SF2 wild type and E167K variant were cultured and HEPA 1–6 cells with zero load plasmids were used as matched control. Flow cytometry was used to detect the cell cycles of these 3 type of HEPA 1–6 cells. Realtime fluores-cence quantitative PCR and western blot were used to analyzed the expression of regulatory factors (Cyclin D1、p53、P16、P27、P21 and Rb) of cell cycle. T-test was used in statistical analysis. RESULTS: Cell cycle phase distribution was presented by the proportion of cells in each phases (%). Compared with the control group, the cell cycle phase distribution (G(1) phase 57.36 ± 0.21%, G(2)/M phase 25.61 ± 0.36%,S phases 19.31 ± 0.25%) had no differences in wild type group (G(1) phase 57.63 ± 0.28%, G(2)/M phase 25.77 ± 0.51%, S phases 19.54 ± 0.25%; P < 0.05). Between variant type group and wild type group,G(1) phase was significantly decreased (variant type group G(1) phase 36.26 ± 0.31%, P < 0.05),S phase and G(2)/M phase were increased(variant type group S phase 28.41 ± 0.31%, P < 0.05;G(2)/M phase 35.23 ± 0.14%, P < 0.05), respectively. Compared with control group,the relative expression of CyclinD1、P53 and Rb mRNA in variant type group was significantly upregulated (2.03 ± 0.01 VS 1.04 ± 0.06, 1.88 ± 0.05 VS 1.37 ± 0.03, 1.29 ± 0.06 VS 1.15 ± 0.03, P < 0.05) and P27 mRNA in variant type group was significantly downregulated (0.56 ± 0.02 VS 0.85 ± 0.05, P < 0.05). Compared with wild type group, the relative expression of CyclinD1、P53 and Rb mRNA in variant type group was significantly upregulated (wild type group 1.00 ± 0.00, 1.48 ± 0.09, 1.18 ± 0.01, P < 0.05) and P27 mRNA in variant type group was significantly downregulated (variant type group 0.82 ± 0.05,P < 0.05). There was no statistical significance between wild type group and control group (P > 0.05). P16 and P21 expression showed no statistical sigtfificance in any of these three groups (P > 0.05). CONCLUSION: E167K polymorphism of TM6SF2 gene affects cell cycles of HEPA1–6 cells via up-regulating CyclinD1、P53 and Rb and down-regulating P27.
format Online
Article
Text
id pubmed-5390375
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53903752017-04-14 E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6 Du, Shuixian Lu, Linlin Miao, Yingxia Jin, Wenwen Li, Changfei Xin, Yongning Xuan, Shiying Lipids Health Dis Research BACKGROUND: Some studties reported that the polymorphism of TM6SF2 gene E167K affects the occurrence and the progression of hepatocytes carcinoma (hepatocellular, HCC). In oeder to investigate the effects of the polymorphism of TM6SF2 gene E167K in the pathogenesis of HCC, we explored its influence on the cell cycle in hepatocellular carcinoma cell HEPA1-6. METHODS: HEPA 1–6 cells which could respectively overexpress TM6SF2 wild type and E167K variant were cultured and HEPA 1–6 cells with zero load plasmids were used as matched control. Flow cytometry was used to detect the cell cycles of these 3 type of HEPA 1–6 cells. Realtime fluores-cence quantitative PCR and western blot were used to analyzed the expression of regulatory factors (Cyclin D1、p53、P16、P27、P21 and Rb) of cell cycle. T-test was used in statistical analysis. RESULTS: Cell cycle phase distribution was presented by the proportion of cells in each phases (%). Compared with the control group, the cell cycle phase distribution (G(1) phase 57.36 ± 0.21%, G(2)/M phase 25.61 ± 0.36%,S phases 19.31 ± 0.25%) had no differences in wild type group (G(1) phase 57.63 ± 0.28%, G(2)/M phase 25.77 ± 0.51%, S phases 19.54 ± 0.25%; P < 0.05). Between variant type group and wild type group,G(1) phase was significantly decreased (variant type group G(1) phase 36.26 ± 0.31%, P < 0.05),S phase and G(2)/M phase were increased(variant type group S phase 28.41 ± 0.31%, P < 0.05;G(2)/M phase 35.23 ± 0.14%, P < 0.05), respectively. Compared with control group,the relative expression of CyclinD1、P53 and Rb mRNA in variant type group was significantly upregulated (2.03 ± 0.01 VS 1.04 ± 0.06, 1.88 ± 0.05 VS 1.37 ± 0.03, 1.29 ± 0.06 VS 1.15 ± 0.03, P < 0.05) and P27 mRNA in variant type group was significantly downregulated (0.56 ± 0.02 VS 0.85 ± 0.05, P < 0.05). Compared with wild type group, the relative expression of CyclinD1、P53 and Rb mRNA in variant type group was significantly upregulated (wild type group 1.00 ± 0.00, 1.48 ± 0.09, 1.18 ± 0.01, P < 0.05) and P27 mRNA in variant type group was significantly downregulated (variant type group 0.82 ± 0.05,P < 0.05). There was no statistical significance between wild type group and control group (P > 0.05). P16 and P21 expression showed no statistical sigtfificance in any of these three groups (P > 0.05). CONCLUSION: E167K polymorphism of TM6SF2 gene affects cell cycles of HEPA1–6 cells via up-regulating CyclinD1、P53 and Rb and down-regulating P27. BioMed Central 2017-04-13 /pmc/articles/PMC5390375/ /pubmed/28407767 http://dx.doi.org/10.1186/s12944-017-0468-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Du, Shuixian
Lu, Linlin
Miao, Yingxia
Jin, Wenwen
Li, Changfei
Xin, Yongning
Xuan, Shiying
E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6
title E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6
title_full E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6
title_fullStr E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6
title_full_unstemmed E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6
title_short E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6
title_sort e167k polymorphism of tm6sf2 gene affects cell cycle of hepatocellular carcinoma cell hepa 1-6
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390375/
https://www.ncbi.nlm.nih.gov/pubmed/28407767
http://dx.doi.org/10.1186/s12944-017-0468-8
work_keys_str_mv AT dushuixian e167kpolymorphismoftm6sf2geneaffectscellcycleofhepatocellularcarcinomacellhepa16
AT lulinlin e167kpolymorphismoftm6sf2geneaffectscellcycleofhepatocellularcarcinomacellhepa16
AT miaoyingxia e167kpolymorphismoftm6sf2geneaffectscellcycleofhepatocellularcarcinomacellhepa16
AT jinwenwen e167kpolymorphismoftm6sf2geneaffectscellcycleofhepatocellularcarcinomacellhepa16
AT lichangfei e167kpolymorphismoftm6sf2geneaffectscellcycleofhepatocellularcarcinomacellhepa16
AT xinyongning e167kpolymorphismoftm6sf2geneaffectscellcycleofhepatocellularcarcinomacellhepa16
AT xuanshiying e167kpolymorphismoftm6sf2geneaffectscellcycleofhepatocellularcarcinomacellhepa16